Mercaptopurine Accord

Mercaptopurine, the active ingredient in Mercaptopurine Accord, is an antimetabolite presented as an oral tablet for systemic use. It is employed in the treatment of certain leukemias and inflammatory bowel diseases, targeting rapidly dividing cells in patients requiring chemotherapy or immunosuppression.

GNH USA supplies Mercaptopurine Accord as a licensed, GDP‑compliant international pharmaceutical supplier, ensuring quality and regulatory compliance while serving hospitals, oncology centres, pharmacies and clinics worldwide. The company focuses on reliable access to essential medicines across diverse markets and timely delivery.

Mercaptopurine is used in antimetabolite therapy for hematologic malignancies and inflammatory bowel disease.

- Acute lymphoblastic leukemia: helps achieve remission by inhibiting leukemic cell proliferation. - Chronic myeloid leukemia: contributes to disease control through cytotoxic effects on myeloid cells. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): reduces inflammation and maintains remission by modulating immune response.

Mercaptopurine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Rash or mild skin irritation - Fatigue - Leukopenia (reduced white blood cells)

Serious or Rare Side Effects: - Bone marrow suppression leading to anemia or severe neutropenia - Hepatotoxicity (elevated liver enzymes or liver injury) - Severe infections due to immunosuppression - Pancreatitis - Secondary malignancies (e.g., therapy‑related leukemia) - Hypersensitivity reactions including Stevens‑Johnson syndrome

When prescribing Mercaptopurine, clinicians should observe several precautionary measures to minimize risks.

- Monitor blood counts: regular CBC testing to detect myelosuppression. - Assess liver function: periodic LFTs due to hepatotoxic risk. - Avoid use in pregnancy: classified as Category D; discuss risks with obstetrician. - Adjust dose in renal impairment: evaluate renal function before therapy. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Mercaptopurine interacts with several medicines; awareness of these interactions helps prevent toxicity or reduced efficacy.

Major Interactions (Avoid): - Allopurinol: co‑administration markedly increases mercaptopurine toxicity. - Azathioprine: combined use can lead to cumulative myelosuppression. - Warfarin: mercaptopurine may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Xanthine oxidase inhibitors (e.g., febuxostat): may raise mercaptopurine levels. - Live vaccines: immunosuppression can reduce vaccine efficacy. - TPMT deficiency: patients with low thiopurine methyltransferase activity require dose adjustment and close monitoring. - Methotrexate: concurrent use may increase hematologic toxicity.